Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6

被引:0
|
作者
H. Hadidi
Y. Irshaid
C. Broberg Vågbø
A. Brunsvik
S. Cholerton
K. Zahlsen
J. R. Idle
机构
[1] Department of Medical Genetics,
[2] Regional Hospital in Trondheim,undefined
[3] Eirik Jarls Gate 10,undefined
[4] N-7006 Trondheim,undefined
[5] Norway e-mail: jeffreyi@medisin.ntnu.no Tel.: +47 73 598879 Fax: +47 73 590560,undefined
[6] Department of Pharmacology,undefined
[7] Faculty of Medicine,undefined
[8] Jordan University of Science and Technology,undefined
[9] Irbid,undefined
[10] Jordan,undefined
[11] Department of Pharmacological Sciences,undefined
[12] Medical School,undefined
[13] Newcastle upon Tyne,undefined
[14] UK,undefined
关键词
Key words Coumarin; Metabolism; Risk evaluation;
D O I
暂无
中图分类号
学科分类号
摘要
Objective: To determine the variability of coumarin 7- and 3-hydroxylation in a human population and to evaluate the evidence for the existence of genetic polymorphism in these pathways. 7-Hydroxylation of coumarin is considered to be a detoxication pathway, whilst 3-hydroxylation, which predominates in rats, leads to hepatotoxicity in the rat. Coumarin metabolic phenotypes could aid in refining the risk evaluation for humans of dietary and environmental exposure to coumarin and for the chronic use of coumarin in high doses as a drug to treat lymphoedema and certain cancers.
引用
收藏
页码:437 / 441
页数:4
相关论文
共 50 条
  • [1] Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6
    Hadidi, H
    Irshaid, Y
    Vågbo, CB
    Brunsvik, A
    Cholerton, S
    Zahlsen, K
    Idle, JR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 437 - 441
  • [2] A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin
    Hadidi, H
    Zahlsen, K
    Idle, JR
    Cholerton, S
    FOOD AND CHEMICAL TOXICOLOGY, 1997, 35 (09) : 903 - 907
  • [3] Functional Characterization of Cytochrome P450 2A6 Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22
    Tiong, Kai Hung
    Yiap, Beow Chin
    Tan, Eng Lai
    Ismail, Rusli
    Ong, Chin Eng
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (05) : 745 - 751
  • [4] Inter-individual Variability of Coumarin 7-hydroxylation (CYP2A6 activity) in an Iranian Population
    Khayyat, Mohammad Hassanzadeh
    Vahdati-Mashhadian, Nasser
    Eghbal, Saeed
    Jalali, Navid
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2013, 16 (04) : 610 - 614
  • [5] POLYMORPHISM OF CYTOCHROME P450 2A6 (CYP2A6*1 AND CYP2A6*4) AMONG JAVA']JAVANESE INDONESIAN SMOKER AND NON SMOKER
    Patramurti, Christine
    Sugiyanto
    Nurrochmad, Arief
    Martono, Sudibyo
    INDONESIAN JOURNAL OF PHARMACY, 2015, 26 (01): : 11 - 19
  • [6] Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants
    Wang, Pan-Fen
    Neiner, Alicia
    Kharasch, Evan D.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (06) : 438 - 445
  • [7] Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis
    Kim, D
    Wu, ZL
    Guengerich, FP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (48) : 40319 - 40327
  • [8] Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population
    Sang Seop Lee
    Hyun-Ju Jung
    Jung Soon Park
    In-June Cha
    Doo-Yeoun Cho
    Jae-Gook Shin
    Molecular Biology Reports, 2010, 37 : 213 - 217
  • [9] Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population
    Lee, Sang Seop
    Jung, Hyun-Ju
    Park, Jung Soon
    Cha, In-June
    Cho, Doo-Yeoun
    Shin, Jae-Gook
    MOLECULAR BIOLOGY REPORTS, 2010, 37 (01) : 213 - 217
  • [10] The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo
    Mirghani, RA
    Hellgren, U
    Westerberg, PA
    Ericsson, O
    Bertilsson, L
    Gustafsson, LL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (05) : 454 - 460